Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Subscribe To Our Newsletter & Stay Updated
